. 2021 Nov 13;14:269. doi: 10.1186/s12920-021-01127-2

Table 1.

Univariable MR results of the effect of genetically predicted atherogenic lipid-related traits on COVID-19 risk

Exposure traits	Outcome traits	N of SNVs	IVW method	MR-Egger regression method	Weighted median method	Weighted mode method	Heterogeneity (IVW method)
Apo-B	COVID-19 susceptibility	128	0.995 (0.93–1.07) 0.89	1.013 (0.91–1.12) 0.81	− 0.0009 (0.0019) 0.64	1.057 (0.93–1.19) 0.38	1.026 (0.93–1.14) 0.63	128.4 0.45
Apo-B	COVID-19 hospitalization	126	0.995 (0.85–1.16) 0.94	0.909 (0.72–1.15) 0.43	0.0040 (0.0041) 0.33	0.902 (0.71–1.15) 0.41	0.881 (0.68–1.15) 0.35	125.7 0.47
Apo-B	COVID-19 severity	130	1.033 (0.82–1.31) 0.79	0.933 (0.64–1.35) 0.71	0.0046 (0.0065) 0.48	0.935 (0.67–1.31) 0.70	0.979 (0.70–1.36) 0.90	172.0 0.007
LDL-C	COVID-19 susceptibility	114	1.048 (0.96–1.14) 0.27	1.028 (0.89–1.18) 0.70	0.0008 (0.0023) 0.74	1.056 (0.93–1.20) 0.41	1.025 (0.90–1.17) 0.71	114.2 0.45
LDL-C	COVID-19 hospitalization	113	0.986 (0.83–1.17) 0.86	0.853 (0.64–1.14) 0.28	0.0057 (0.0046) 0.22	0.892 (0.68–1.17) 0.41	0.889 (0.67–1.18) 0.42	108.5 0.58
LDL-C	COVID-19 severity	115	1.034 (0.83–1.29) 0.77	0.806 (0.54–1.21) 0.30	0.0099 (0.0067) 0.14	0.882 (0.62–1.26) 0.49	0.949 (0.65–1.38) 0.79	127.1 0.19
TG	COVID-19 susceptibility	208	1.065 (1.00–1.13) 0.045	1.101 (0.99–1.21) 0.052	− 0.0014 (0.0016) 0.36	1.099 (0.99–1.22) 0.07	1.079 (0.98–1.19) 0.13	235.9 0.08
TG	COVID-19 hospitalization	205	1.174 (1.04–1.33) 0.012	1.275 (1.06–1.53) 0.010	− 0.0036 (0.0030) 0.23	1.167 (0.96–1.42) 0.12	1.201 (1.01–1.43) 0.039	192.5 0.71
TG	COVID-19 severity	208	1.274 (1.08–1.50) 0.004	1.310 (1.03–1.67) 0.030	− 0.0013 (0.0040) 0.75	1.201 (0.92–1.57) 0.18	1.160 (0.91–1.47) 0.22	210.2 0.43

Exposure traits

Outcome traits

N of SNVs

IVW method

MR-Egger regression method

Weighted median method

Weighted mode method

Heterogeneity (IVW method)

OR (95% CI)
P-value

Intercept (SE)
P-value

OR (95% CI)
P-value

Cochran’s Q
P-value

Apo-B

COVID-19 susceptibility

128

0.995 (0.93–1.07)

0.89

1.013 (0.91–1.12)

0.81

− 0.0009 (0.0019)

0.64

1.057 (0.93–1.19)

0.38

1.026 (0.93–1.14)

0.63

128.4

0.45

Apo-B

COVID-19 hospitalization

126

0.995 (0.85–1.16)

0.94

0.909 (0.72–1.15)

0.43

0.0040 (0.0041)

0.33

0.902 (0.71–1.15)

0.41

0.881 (0.68–1.15)

0.35

125.7

0.47

Apo-B

COVID-19 severity

130

1.033 (0.82–1.31)

0.79

0.933 (0.64–1.35)

0.71

0.0046 (0.0065)

0.48

0.935 (0.67–1.31)

0.70

0.979 (0.70–1.36)

0.90

172.0

0.007

LDL-C

COVID-19 susceptibility

114

1.048 (0.96–1.14)

0.27

1.028 (0.89–1.18)

0.70

0.0008 (0.0023)

0.74

1.056 (0.93–1.20)

0.41

1.025 (0.90–1.17)

0.71

114.2

0.45

LDL-C

COVID-19 hospitalization

113

0.986 (0.83–1.17)

0.86

0.853 (0.64–1.14)

0.28

0.0057 (0.0046)

0.22

0.892 (0.68–1.17)

0.41

0.889 (0.67–1.18)

0.42

108.5

0.58

LDL-C

COVID-19 severity

115

1.034 (0.83–1.29)

0.77

0.806 (0.54–1.21)

0.30

0.0099 (0.0067)

0.14

0.882 (0.62–1.26)

0.49

0.949 (0.65–1.38)

0.79

127.1

0.19

COVID-19 susceptibility

208

1.065 (1.00–1.13)

0.045

1.101 (0.99–1.21)

0.052

− 0.0014 (0.0016)

0.36

1.099 (0.99–1.22)

0.07

1.079 (0.98–1.19)

0.13

235.9

0.08

COVID-19 hospitalization

205

1.174 (1.04–1.33)

0.012

1.275 (1.06–1.53)

0.010

− 0.0036 (0.0030)

0.23

1.167 (0.96–1.42)

0.12

1.201 (1.01–1.43)

0.039

192.5

0.71

COVID-19 severity

208

1.274 (1.08–1.50)

0.004

1.310 (1.03–1.67)

0.030

− 0.0013 (0.0040)

0.75

1.201 (0.92–1.57)

0.18

1.160 (0.91–1.47)

0.22

210.2

0.43

Apo-B, apolipoprotein B; CI, confidence interval; COVID-19, coronavirus disease 2019; IVW, inverse variance weighted; LDL-C, low-density lipoprotein cholesterol; MR, Mendelian randomization; N, number; OR, odds ratio; SE, standard error; SNV, single nucleotide variant; TG, triglyceride